David Bredt, Chief Scientific Officer at Rapport Therapeutics, Inc. (RAPP), sold 8,500 shares at $10.85 ($92K) on 2025-03-14, disclosed to the SEC on 2025-03-17.
Scheduled sale ($92k) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| RAPP | SELL | 2026-01-05 | $395K | — | Filing → |
| RAPP | SELL | 2025-12-16 | $486K | — | Filing → |
| RAPP | SELL | 2025-11-18 | $428K | — | Filing → |